Shaping better health
REMEDY : BNSSG referral pathways & Joint Formulary


Home > Adults > Biochemistry >

Hyperlipidaemia

Checked: 28-03-2024 by 3 Vicky Ryan Next Review: 27-03-2026

Lipid Guidelines

Local lipid specialists at UHBW/NBT have worked with ICB pharmacy colleagues to produce a new bundle of guidelines summarising the diagnosis and monitoring of lipid disorders.

  • The bundle seeks to standardise and consolidate lipid advice across both primary and secondary care. The bundle incorporates the NHS England national lipid management and statin intolerance pathways (adopted recently by the BNSSG APMOC group) as well as summaries on core topics such as:
    • Hypertriglyceridemia diagnosis and management
    • Lipoprotein (a) measurement and interpretation
    • Secondary prevention pathways
    • Non-statin/Ezetimibe therapies (including injectable technologies and Inclisiran)

The guidelines have been designed to consolidate guidance across several sources and be easily navigated by clinicians with algorithms. If you have any concerns about the content or presentation of the new bundle please get in contact with Dr Paul Downie/Dr Eloise Willis (paul.downie@uhbw.nhs.uk   / eloise.willis@uhbw.nhs.uk) from the UHBW lipid clinic.

Specific guidelines

This guideline acts a repository of all the relevant guidelines for the diagnosis and management of lipid disorders locally within the Bristol, North Somerset, South Gloucestershire Integrated Care Board (BNSSG ICB).

Guidelines have been collated from national management pathways available publicly online and local pathways created by local lipid specialists in collaboration with relevant specialities.

Patients reviewing this guideline should be mindful that local clinicians are able to use these guidelines at their discretion and in light of factors individual to you.

Each box below is a hyperlink to the relevant guideline




Additional information on lipid diagnosis and management:




Efforts are made to ensure the accuracy and agreement of these guidelines, including any content uploaded, referred to or linked to from the system. However, BNSSG ICB cannot guarantee this. This guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer, in accordance with the mental capacity act, and informed by the summary of product characteristics of any drugs they are considering. Practitioners are required to perform their duties in accordance with the law and their regulators and nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.

Information provided through Remedy is continually updated so please be aware any printed copies may quickly become out of date.